Press releases
Â鶹Æƽâ°æ strengthens its business team to support International growth
Lyon, the 10th of May 2017. Â鶹Æƽâ°æ, a biopharmaceutical company currently focused on developing treatments for viral infections, has today announced that it is strengthening its business team with the appointment of a CFO and a VP Corporate Development and Strategy, both individuals having strong experience in the pharmaceutical businesses.
Â鶹Æƽâ°æ announces successful initiation of the Phase 1 clinical programme with EYP001, its lead candidate for the treatment of Chronic Hepatitis B Virus infection.
Lyon, December 16, 2016 – Â鶹Æƽâ°æ, a privately held biopharmaceutical company currently focused on developing treatments for viral infections, today announced that the Phase 1 single and multiple ascending dose trial evaluating EYP001 in healthy subjects has been initiated, and that single dose escalation has been completed. The results have shown that EYP001 is safe and well-tolerated at all doses studied in 46 healthy subjects. The safety and pharmacokinetics (PK) analysis of these first Phase 1 data will be complete by Q2 2017.
Â鶹Æƽâ°æ receives a €2.5 million grant from EU under the Horizon2020/SME Instrument Phase 2 programme for its project MIMESIS
Lyon, December 5, 2016 – Â鶹Æƽâ°æ, a biopharmaceutical company currently focused on developing treatments for viral infections, today announced that it has received a grant of €2.5 million in response to its application to the highly competitive SME Instrument Phase 2 funding programme (6% success rate).
Â鶹Æƽâ°æ strengthens its management team to support its strategy of international growth
Lyon, November 7, 2016 – Â鶹Æƽâ°æ strengthens its management team to support its strategy of international growth.
Â鶹Æƽâ°æ announces closing of a €22 million funding round
Lyon, February 3, 2016 – Â鶹Æƽâ°æ announces closing of a €22 million funding round.
